Background/Objectives: Classical swine fever (CSF) is listed by the World Organisation for Animal Health as a highly devastating and contagious pig disease, causing severe economic losses to the swine industry. In spite of the successful elimination of CSF in Taiwan, preparedness against potential reintroduction remains essential. The live attenuated vaccines have been effective in disease control, but are not capable of a viable strategy that differentiates infected from vaccinated animals (DIVA). Subunit vaccines are recognized for their safety and ability to induce protective immunity against infectious diseases. Methods: In this study, the recombinant CSF virus (CSFV) E2 proteins were formulated with a CpG motif as an adjuvant to produce the E2-CpG subunit vaccine. Its efficiency in specific-pathogen-free (SPF) pigs was compared with a commercially available E2 subunit vaccine (Bayovac® CSF-E2; Bayer Taiwan Co., Ltd., Taipei City, Taiwan). Results: Significantly higher titers of anti-E2 antibodies were induced in pigs immunized with a single dose of the E2-CpG vaccine, particularly the reduced E-0.5A formulation, than those immunized with a dose of the commercialized E2 subunit vaccine adjusted to double dosage. This designed subunit vaccine showed high efficacy in protection against clinical symptoms and significant pathological alterations in pigs after a highly virulent CSFV (genotype 1.1) challenge. Viral shedding was not detected in vaccinated pigs before completion of the challenge study, and the viral load in their spleens remained undetectable. Conclusions: These results could support the potential of the E2-CpG vaccine as a cost-effective, single-dose subunit vaccine capable of inducing robust CSFV-specific immunity and providing 100% protection against lethal CSFV challenges.
Background: The study of specific T-cell responses to vaccines against CSFV is important for understanding long-term immunity and infection management. The administration of a subunit vaccine against swine pathogens has been demonstrated to be safe and effective in infected pigs. However, subunit vaccines usually need an effective immunomodulatory adjuvant to stimulate active immune responses. Objectives: CD86 plays a crucial role in the immune response by enhancing the ability of APCs to stimulate the maturation and activation of T lymphocytes. Therefore, CD86 may act as a potential molecular adjuvant due to its ability to increase cytokine expression, which is protective against T-cell activation in pathogens. Methods: In this study, the CD86 coding sequence was linked with the CSFV E2 antigen sequence and then expressed in CHO cells for production of the fusion protein as an E2-CD86 vaccine. Commercial pigs aged 5–6 weeks were randomized into four groups: those inoculated with E2, E2-CD86, commercial Bayovac® CSF-E2 vaccines and the saline group. All animals were boosted 2 weeks after primary vaccination. Results: After vaccination, we evaluated the humoral response and compared it with that of T cells with the aim of correlating both types of responses and increasing CSFV-specific E2 antibody detection. The results revealed that the percentages of CD3+CD4+/CD8+, CD4+IL2+, IFNγ+ and CD4+CD8+ (DP) T cells among the PBMC 14 days after primary vaccination were significantly greater in the E2-CD86 group than in the other groups. The ELISpot results revealed a significant increase in the number of E2-specific IFNγ+ cells on D21 after vaccination. Conclusions: These results suggest that CD86 may enhance cellular immunity by increasing the levels of IL-2 and IFNγ-positive cells. Therefore, CD86 can act as a potential immuno-modulatory adjuvant in the development of subunit vaccines because of its protective efficacy.
CD154 plays a central role in the development and regulation of adaptive immune responses in mammals and thus may act as a potential molecular adjuvant due to its enhancement of cytokine expression in immune cells. In this study, CD154-coding sequence was linked with the E2 antigen sequence of the Classical swine fever virus (CSFV) to produce an E2-CD154 vaccine and the specific pathogen free piglets at the age of 4-week old was used as an animal model. The CpG adjuvant, a Toll-like receptor 9 agonist, was used as a positive control. The animals were randomized into three groups and primarily vaccinated with E2-CD154, E2-CpG or the commercial Bayovac® E2 vaccines, respectively. All animals were boosted 2 weeks after primary vaccination. Results showed that the percentages of CD3+CD4+, CD4+IL2+ and CD4+IFNγ+ T cells in the peripheral blood mononuclear cells on 7-d (7 days) after primary vaccination were significantly enhanced in the E2-CD154 group as compared with the other two groups. Noteworthy, CD8+IL-2+ populations were increased on 21-d and CD4+IL2+ showed the highest expression on 28-d after booster in those of the E2-CD154 group. In addition, significantly increased E2-specific IFNγ+ cells were found on 10-d and 14-d after the primary vaccination and 21-d and 28-d after booster in those of the E2-CD154 group. These results indicate that CD154 elevated T cells activities for producing high levels of IL-2 and IFN-γ. Thus, CD154 may act as a potential immunomodulatory adjuvant by increasing antigen-specific positive IFNγ-expressing cells.
Background/Objectives: Porcine Circovirus Type 2 (PCV2) impairs pigs’ immune systems and increases susceptibility to co-infections, including Classical Swine Fever (CSF), a highly contagious disease listed by the World Organisation for Animal Health (WOAH) as notifiable. Therefore, swine operations in CSF-endemic regions are encouraged to immunize piglets with both PCV2 and CSFV vaccinations. Currently, there is no commercially available bivalent vaccine for PCV2/CSFV. Methods: In this study, a total of twenty 4-week-old SPF pigs were administered our formulated PCV2/CSFV bivalent subunit vaccine, containing soluble CSFV-E2 (50 µg) and PCV2-ORF2 (100 µg) antigens with a porcine-specific CpG adjuvant. After 4 weeks of vaccination, all pigs were evaluated for efficacy against PCV2 and CSFV. Results: Pigs were only immunized once and showed significantly increased neutralizing or ELISA antibody titers against both viruses four weeks post-vaccination. After viral challenges, vaccinated pigs displayed no clinical signs or lesions and had markedly reduced CSFV and PCV2 viral loads in the serum and tissues compared to controls. Conclusions: These results demonstrate that a single dose of the PCV2/CSFV bivalent subunit vaccine is safe and effective in young pigs, induces strong antibody responses, and suppresses viral replication, making it a promising tool for swine disease control and cost-effective vaccination strategies.